Recro Pharma (NASDAQ: REPH) is a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of acute post operative pain. Recro Pharma is currently developing IV/IM Meloxicam, a proprietary, Phase III-ready, rapid-onset, long-acting preferential COX-2 inhibitor, and Dex-IN, a proprietary intranasal formulation of dexmedetomidine in Phase II, both for the treatment of acute post operative pain. As Recro Pharma's product candidates are not in the opioid class of drugs, the Company believes its candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory distress while maintaining analgesic effect. Recro Pharma owns and operates an 97,000 square foot, DEA-licensed facility that manufactures five commercial products that are commercialized by partners and receives royalties associated with the sales of these products. Source
No articles found.
Restoration Robotics, Inc., (San Jose, CA) is a medical device company developing ...
Restoration Robotics, Inc., (San Jose, CA) is a...
China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company based in T...
China SXT Pharmaceuticals, Inc. is an innovativ...
Today's adults juggle caring for aging parents and children while working full-tim...
Today's adults juggle caring for aging parents ...
Amphastar Pharmaceuticals, Inc., headquartered in Rancho Cucamonga, California, es...
Amphastar Pharmaceuticals, Inc., headquartered ...
Scopus BioPharma develops small molecule therapeutics leveraging world-class exper...
Scopus BioPharma develops small molecule therap...
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by si...
Arrowhead Pharmaceuticals develops medicines th...
NuvectraÂŽ is a neurostimulation company committed to helping physicians improve t...
NuvectraÂŽ is a neurostimulation company commit...
Join the National Investor Network and get the latest information with your interests in mind.